The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM).
J. M. G. Larkin
No relevant relationships to disclose
S. Turajlic
No relevant relationships to disclose
P. D. Nathan
No relevant relationships to disclose
P. Lorigan
No relevant relationships to disclose
G. Stamp
No relevant relationships to disclose
D. Gonzalez de Castro
No relevant relationships to disclose
N. Martin
No relevant relationships to disclose
J. Griffiths
No relevant relationships to disclose
K. Edmonds
No relevant relationships to disclose
S. Sarker
No relevant relationships to disclose
M. G. James
No relevant relationships to disclose
R. A'Hern
No relevant relationships to disclose
G. Coombes
No relevant relationships to disclose
C. Snowdon
No relevant relationships to disclose
J. M. Bliss
No relevant relationships to disclose
M. E. Gore
No relevant relationships to disclose
R. Marais
No relevant relationships to disclose